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Abstract
Purpose: To look at the presenting features, Enneking stage, size of primary tumour, method of treatment and patient and
doctor delays in upper extremity Ewing’s sarcoma to observe the effects on local recurrence, metastasis and survival.
Patients and methods: Nineteen patients with upper extremity Ewing’s sarcoma were identified using the Scottish Bone
Tumour Registry over the past 40 years.
Results: With increasing tumour Enneking stage at presentation there was a significantly higher mortality (P¼0.02).
Patients with a higher Enneking stage also had an increased trend towards local recurrence (P¼0.08). Stage did not
influence the occurrence of metastasis. Patients with larger tumours tended to have a higher mortality (50 vs. 27% dead at 5
years). All patients presented clinically with pain and all but two complained of some sort of swelling. There was a trend
towards a higher Enneking Stage in patients presenting with a longer duration of symptoms (P¼0.1). No difference in
survival was noted between patients undergoing surgery and chemotherapy and patients undergoing radiotherapy and
chemotherapy. Disease-free survival was 100% at both 5 and 10 years for Enneking stage IIA, 56% at 5 and 10 years for
stage IIB and 0% at 5 years for stage III.
Discussion: This study re-emphasises the potential importance of a diagnostic delay on outcome. Longer symptom duration
is associated with a higher Enneking stage at presentation. In turn a higher presenting stage results in a higher mortality.
Pain and swelling are prominent clinical findings at first presentation in upper extremity Ewing’s.
Introduction
Ewing’s sarcoma is a rare malignant tumour occur-
ring primarily in bone but also not uncommonly in
soft tissue. Presenting mainly in the second decade of
life it has a predilection for the pelvis, the ribs and the
diaphyses of long bones. At the time of presentation,
approximately 25% of people have radiological
metastases. Prior to chemotherapy the relapse rate
was approaching 80%, suggesting systemic
spread for many people at the time of diagnosis.
The treatment of Ewing’s sarcoma currently involves
a multidisciplinary approach. The use of four-agent
chemotherapy has revolutionised the prognosis in
Ewing’s sarcoma,[1,2] but some debate still remains
as to whether radiotherapy or surgery for localised
lesions is superior in terms of survival [3–7].
In the upper extremity, the effects of surgery may
have far-reaching consequences in terms of function
of the upper limb and hand, particularly in the case
of amputation. While there is an increased risk of
second malignancy with radiotherapy,[8,9] it has a
less disabling impact on function compared to
surgery. If there is no survival advantage with surgery
for patients developing tumours in the upper
extremity then it may be more appropriate to
recommend radiotherapy as an adjunct to
chemotherapy. In this study the Scottish experience
of the presentation and treatment of Ewing’s
sarcoma in the upper extremity over the last 40
years was analysed to see if any recommendations
could be made regarding the most appropriate
treatment modalities for these patients.
Analysis was made of the presenting features,
Enneking stage [10] size of primary tumour and
patient and doctor delays to observe the effects on
local recurrence, metastasis and survival.
Patients and methods
The Scottish Bone Tumour Registry is a clinical,
pathological and radiological database on the
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the last 40 years. The Registry was used to identify
19 patients who had been treated for Ewing’s
sarcoma of the upper limb including the shoulder
girdle. Data were gathered on patient age, presenting
features, radiographic features, time to diagnosis and
treatment, type of treatment, complications, and
survival. All archival pathology was reviewed by an
experienced musculo-skeletal histopathologist to
confirm diagnosis.
The chi-square test was used for statistical analysis.
The significance level was set at P<0.05. Kaplan–
Meier statistics were used to calculate survival data.
Results
Nineteen cases of upper limb Ewing sarcoma were
identified from the database, 14 of whom were male
and five of whom were female. Their ages ranged
from 3 to 57 years, with a mean age of 19 years.
Review of the histology confirmed that the recorded
diagnosis of Ewing’s sarcoma on the database was
correct in each case. Details of patient demographics,
presenting symptoms, tumour site and follow up can
be seen in table 1.
Time from symptom onset to first doctor appointment –
patient delay
Patient delay varied from 1 to 180 months with a
median of 6 months. When the patient delay was
compared with Enneking stage at presentation there
was a trend towards a higher stage at presentation
with longer symptoms (P¼0.1).
Time from first doctor appointment to definitive diagnosis
– doctor delay
Doctor delay varied from 1 to 128 weeks with a
median of 5 weeks.
Radiographic features
Original radiographic images were available for
analysis in 17 of the patients. Eleven patients had
tumours which were less than 80mm in maximum
dimension, while six had tumours of greater size than
this. Patients with larger tumours tended to have a
higher mortality (50 vs. 27% dead at 5 years).
Treatment
Chemotherapy
Sixteen of the 19 patients underwent neoadjuvant
chemotherapy (table 2).
Two others, who were treated in 1965 and
1971, had only radiotherapy for their tumours.
Ten patients had four-agent chemotherapy, while
six had three-agent chemotherapy. One other patient
was given single-agent chemotherapy for palliative
purposes.
Radiotherapy
Fifteen of the 19 patients were treated
with radiotherapy. Nine had their therapy as part
of the primary treatment, while six others
underwent radiotherapy for palliative purposes only.
All primary radiotherapy treatments were of high
dose (45–60Gy). There were no cases of second
malignancies reported in the registry, although one
patient was lost to follow-up when he moved back
to Africa.
Surgery
Twelve of the 19 patients underwent surgery. Fifteen
procedures were carried out in total, and in 10
instances this was performed as part of the primary
tumour treatment.
Following inadequate resection margins in three
patients, further surgery was performed with two
forequarter amputations and a wide local excision of
residual clavicle. A forearm amputation was
performed palliatively in one patient who had not
undergone any primary surgical treatment and one
further patient underwent a thoracic laminectomy to
palliate spinal metastasis.
Chemotherapy and surgery
Five cases were identified where chemotherapy and
surgery were the primary treatment modalities.
One was Enneking stage IIA, while the other four
Table I. Patient demographics, presenting features and length of
follow-up
Number of patients: 19
Age range: 3–57 (mean 19)
Gender: Male: 14
Female 5
Site: Shoulder girdle: 2
Humerus: 11
Forearm: 4
Hand: 2
Presenting Features: Pain: 19
Night pain 5
Severe pain 2
Swelling: 17
Neurological symptoms: 2
Loss of Function: 7
Length of follow-up:
-All patients: Range of 6–392 months
Median 30 months
Mean 81 months
-Survivors: Median 149 months
Mean 165 months
One patient lost to follow-up when he returned to the African
continent after 6 months disease free
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Year of
diagnosis
Age Gender Site Enneking grade Chemotherapy Treatment Surgery Survival
Radiotherapy
(dose, Gy)
1965 7 F Proximal humerus IIA No Yes(60) No Alive disease-free
1970 9 F Proximal humerus IIA No Yes(45) No Alive disease-free
1972 15 M Proximal humerus III Single agent
palliative
Yes(40) Palliative
laminectomy
Died 9 months
1974 24 M Proximal humerus IIB Three-agent Yes(50) No Alive disease-free
1980 17 M Proximal humerus III Three-agent Yes(60) No Died 1 year
þ2 months
1980 8 F Proximal humerus IIA Three-agent Yes(60) No Died 1 year
þ2 months
1988 17 M Radius IIB Four-agent Yes(60) Radial
excision
Alive disease-free
1989 11 M Radius III Three-agent Yes
(unknown for
palliation)
Forearm amputation Died 1 year
þ4 months
1989 3 M Proximal humerus IIB Three-agent Yes(50) No Alive disease-free
1989 12 M Radius IIA Four-agent Yes(55) No Alive disease-free
1992 16 F Clavicle IIB Four-agent No Excision
of clavicle
Died 1 year
þ2 months
1993 28 M Phalanx IIB Three-agent No Triple ray
resection
(metacarpal)
Alive disease-free
1996 17 M Phalanx III Four-agent Yes(54) Ray amputation
(metacarpal)
Died 4 years
þ3 months
1997 31 M Proximal humerus IIB Four-agent Yes(55 primarily
then 20þ20 palliative)
Proximal humeral
endoprosthesis
Died 1 year
þ8 months
1998 14 M Proximal humerus IIB Four-agent Yes(50) Humeral resection
þfibular graft
Died 2 years
þ6 months
1998 45 M Radius IIA Four-agent Yes(50) Radial excision Lost to f/u at
6 months
1999 7 F Proximal humerus IIB Four-agent Yes(60) Humeral resection
þfibular graft
Alive recurrent
disease
2001 23 M Proximal humerus IIA Four-agent No Proximal humeral
endoprosthesis
Alive disease-free
2002 57 M Clavicle IIB Four-agent No Excision of clavicle Alive disease-free
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7were stage IIB. There was one disease-related
mortality in the IIB group.
Chemotherapy and radiotherapy
Six patients had chemotherapy and radiotherapy as
their primary tumour treatment. They tended to
have presented with slightly higher Enneking stages
of tumour, with two patients staged at grade III, two
at IIB and two at IIA. Both patients who had
metastases at the time of diagnosis died of their
tumours, while one patient in the IIB group died of
a chemotherapy-related complication. The patient
did not have any evidence of residual disease at
autopsy. The two patients with stage IIA disease are
still alive.
Enneking stage at presentation versus metastasis, survival
and local recurrence
The Enneking stage at presentation did not appear to
be related to the presence of clinically identifiable
metastasis. Higher Enneking stage at presentation
was, however, associated with a significantly greater
mortality (P¼0.02). With regard to local recurrence
following treatment, there was a trend towards local
recurrence in higher stage tumours (P¼0.08).
Disease-free survival
Ten-year disease-free survival was 100% for patients
with Enneking stage IIA disease and 56% with IIB
disease. For stage III disease there were no survivors.
Discussion
Despite being the second most common primary
bone tumour, Ewing’s sarcoma is still rare. Its annual
incidence is approximately 0.8 per million
population [11]. Even specialist oncological sur-
geons may see only a handful of cases. Ewing’s of the
upper extremity is seen even less frequently. This
poses particular problems when it comes to identify-
ing patients with a tumour and subsequently decid-
ing the most appropriate management. Previous
studies have looked at the presenting symptoms
and clinical features of Ewing sarcoma based on data
collected at the oncology clinic when a diagnosis was
either suspected or confirmed [12,13]. Widhe et al.
[14] looked at the presenting symptoms and clinical
features of Ewing from the first visit to a physician
but none of the patients in their series of 48 had a
tumour of the upper extremity. In this series, details
of the presenting complaints and physical findings
found on the first physician visit were also available,
so a direct comparison of presenting features
was possible between patients with upper
extremity Ewing and patients with tumours in other
anatomical areas.
In this study tumours occurred almost 3 times as
often in males when compared to females, and the
mean age was 19 years. These findings concur with
previous large studies of Ewing sarcoma. [15,16]
All patients presented with pain, and 17 of the 19
(84%) complained of a mass which was palpable on
examination. This is greater than the experience of
other studies and may be explained by the relative
lack of soft tissue coverage in the upper limb. Night
pain, which is frequently considered a hallmark of a
bone malignancy, was uncommon, occurring in only
26% of cases. The absence of night pain therefore
should not be a reassuring feature.
The two patients who complained of neurological
symptoms both died and were found to have
Enneking stage III tumours at diagnosis. This is,
perhaps, not surprising, with features of neural
invasion in most tumours also frequently heralding
a poor prognosis.
The median diagnostic delay for this series was 35
weeks which is very similar to other published series
[14,17,18]. The vast majority of this delay was due to
patient factors (30 weeks) and may have occurred due
to the intermittent nature of the symptoms described
(52% of patients) or the fact that symptom onset was
associated with trauma (37% of patients). In one case
the doctor-associated delay was particularly pro-
longed due to an incorrect diagnosis of osteomyelitis
being given. This unfortunate pitfall has been
described previously. [19] The tendency of patients
with Ewing’s tumour to have symptoms and signs of
sepsis and the necessity for submission of material
fromanycaseofsuspectedboneinfectionforhistology
as well as culture cannot be overstated.
The length of symptom duration did not affect the
presenting Enneking stage significantly, although it
was found that in those who presented with tumours
of higher stage there was a significantly higher
mortality and a trend towards increased local
recurrence.
Increased tumour sizes on imaging was associated
with a trend towards increased mortality in accor-
dance with the work of Hayes et al.[20] and other
published series.
Over time there was considerable heterogeneity in
the treatment regimes seen. This was probably as a
result of the introduction and improvement of
chemotherapy and the fact that little evidence existed
regarding the best use of radiotherapy or surgery.
It is interesting to note the difference in incidence
between the number of tumours diagnosed in the
first 20 years of the registry when compared to
the second 20 years (six versus 13 cases). It is not
known if this is as a result of a genuine increase in
the incidence of these tumours. From 1975 to 1999
the National Cancer Registry has collected informa-
tion on cases of Ewing’s sarcoma in children
(0–14 years). [21] During this period 61 cases were
recorded in total. Over the same period only 49 cases
18 P.M.S. Simpson et al.of Ewing’s sarcoma were documented in the Scottish
Bone Tumour Registry, suggesting that some of the
differences observed in the incidence of Ewing’s
sarcoma during the 40year period may be related to
incomplete registry. Similar statistics for adults are
not available for Ewing’s sarcoma in isolation.
The small numbers in this study preclude any
meaningful comparison between patients treated
with adjuvant radiotherapy or surgery following
chemotherapy, although there were no obvious
differences between the groups in terms of overall
survival. This concurs with the data from the CESS-
86 study which found no differences in survival
between patients treated with surgery or radiotherapy
for localised disease [6,7]. Surgery was found to be
superior to radiotherapy in terms of local recurrence,
however (11 vs. 20%), with the reverse being the case
for metastasis. The most common site of Ewing’s in
the upper limb is the proximal humerus. Forequarter
amputation clearly has far-reaching functional con-
sequences, so a number of limb-sparing surgical
strategies have been devised. These involve humeral
resection and replacement with either a modular
endoprosthesis (Figure 1) or a bulk allograft. If the
most proximal and distal segments of the humerus
can be preserved then a vascularised autograft is also
a possibility. While these have produced good results
in terms of elbow, forearm and hand function, the
results at the shoulder were generally poor. [22–24]
Allografts suffer a high failure rate, while endo-
prostheses can suffer from painful subacromial
impingement secondary to deltoid resection, rotator
cuff dysfunction and proximal migration of the
prosthesis. Frequently the shoulder ends up stiff.
Radiotherapy offers an alternative treatment to
surgery, although it also has its problems. Acutely
this may mean skin breakdown or lymphoedema.
In the long term, radiotherapy may result in tissue
atrophy, fibrosis and muscle contracture, pathologi-
cal fracture or second neoplasm. In addition radio-
graphs and bone scans can continue to be abnormal
for many years following treatment hindering
the interpretation of local recurrence. Functional
outcome in the upper limb does appear to be better,
however [25]. There were no cases of second
malignancies in this series. This may due to the
relatively short follow-up, with many of the cases
having being diagnosed in the last 10 years or the fact
that the risk of a second malignancy has been shown
to be quite low at 4.7% after 15 years [26].
In conclusion, although the biological behaviour of
Ewing’s tumours of the upper extremity is similar to
Ewing’s found in other regions of the body and the
presenting symptoms and examination findings are
comparable to previous studies, far more upper limb
tumours appear to be palpable at the time of
presentation. Furthermore, patient delay makes the
largest contribution to diagnostic delay and may
affect the Enneking stage at presentation. A higher
Enneking stage at presentation was found to have a
significant effect on survival. The development of an
algorithm to alert primary physicians to important
worrying features such as swelling may be of value in
the upper limb. The question of whether radio-
therapy or surgery in addition to chemotherapy is
superior in terms of survival remains to be answered.
In current practice surgery still seems to be the
preferred modality of choice for the control of
localised Ewing’s tumours.
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